Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409481 | 0.92 | MEN1 (0.39) | SLC6A4MEN1KMT2AALDH1A1BCHE | |
| SCHEMBL25325372 | 0.88 | CYP2D6 (0.35) | MEN1KMT2ARORCALDH1A1CYP2D6 | |
| SCHEMBL25325419 | 0.87 | ENPP2 (0.41) | RORCBCHEACHECYP2D6 | |
| SCHEMBL25327985 | 0.86 | GPR119 (0.38) | SLC6A4RORCALDH1A1CYP2D6KCNH2 | |
| SCHEMBL27144502 | 0.84 | BCHE (0.48) | SLC6A4MEN1KMT2AALDH1A1BCHE | |
| SCHEMBL23148927 | 0.84 | IDO1 (0.41) | IDO1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL21984758 | 0.83 | IDO1 (0.55) | IDO1SLC6A4NAAASLC6A2SLC6A3 | |
| SCHEMBL21723030 | 0.82 | HTR2A (0.43) | SLC6A4RORCALDH1A1BCHEACHE | |
| SCHEMBL29712505 | 0.82 | HTR2A (0.43) | SLC6A4RORCALDH1A1BCHEACHE | |
| SCHEMBL30945261 | 0.82 | SLC6A4 (0.43) | SLC6A4MEN1KMT2AALDH1A1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204420-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20230203056-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4034239-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114364684-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109715613-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| WO-2021058416-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021058444-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | IDO1 1210/4885SLC6A4 2865/4885MEN1 96/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | IDO1 1210/4885SLC6A4 2865/4885MEN1 96/4885 |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | IDO1 1695/4885SLC6A4 880/4885MEN1 183/4885 |
| US-20230203056-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, ZYX, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IDO1 1008/4885SLC6A4 4212/4885MEN1 134/4885 |
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP1A1 | IDO1 797/4885SLC6A4 4083/4885MEN1 210/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | IDO1 1695/4885SLC6A4 880/4885MEN1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.